Difference between revisions of "MOC31"

Jump to navigation Jump to search
489 bytes added ,  16:30, 15 May 2016
no edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
'''MOC31''' is an [[immunostain]].
'''MOC31''' is an [[immunostain]]. The antibody is directed against the epithelial cell adhesion molecule (Ep-CAM, TACSTD1).<ref name=pmid19391212/>
 
It is useful for differentiating [[hepatocellular carcinoma]] from [[cholangiocarcinoma]] and [[liver metastases]].<ref name=pmid10937059>{{Cite journal  | last1 = Proca | first1 = DM. | last2 = Niemann | first2 = TH. | last3 = Porcell | first3 = AI. | last4 = DeYoung | first4 = BR. | title = MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers. | journal = Appl Immunohistochem Mol Morphol | volume = 8 | issue = 2 | pages = 120-5 | month = Jun | year = 2000 | doi =  | PMID = 10937059 }}</ref>


==Negative==
==Negative==
*[[Hepatocellular carcinoma]].<ref name=pmid10937059/>
*[[Hepatocellular carcinoma]].<ref name=pmid10937059>{{Cite journal  | last1 = Proca | first1 = DM. | last2 = Niemann | first2 = TH. | last3 = Porcell | first3 = AI. | last4 = DeYoung | first4 = BR. | title = MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers. | journal = Appl Immunohistochem Mol Morphol | volume = 8 | issue = 2 | pages = 120-5 | month = Jun | year = 2000 | doi =  | PMID = 10937059 }}</ref>
*[[Malignant mesothelioma|Malignant epithelioid mesothelioma]] - usually negative.<ref name=pmid9490276/>
*[[Malignant mesothelioma|Malignant epithelioid mesothelioma]] - usually negative.<ref name=pmid9490276/>


Line 11: Line 9:
*[[Liver metastases]].<ref name=pmid10937059/>
*[[Liver metastases]].<ref name=pmid10937059/>
*[[Lung adenocarcinoma]].<ref name=pmid9490276>{{Cite journal  | last1 = Ordóñez | first1 = NG. | title = Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. | journal = Hum Pathol | volume = 29 | issue = 2 | pages = 166-9 | month = Feb | year = 1998 | doi =  | PMID = 9490276 }}</ref>
*[[Lung adenocarcinoma]].<ref name=pmid9490276>{{Cite journal  | last1 = Ordóñez | first1 = NG. | title = Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. | journal = Hum Pathol | volume = 29 | issue = 2 | pages = 166-9 | month = Feb | year = 1998 | doi =  | PMID = 9490276 }}</ref>
*[[Invasive ductal carcinoma of the breast]].<ref name=pmid19391212>{{Cite journal  | last1 = Pai | first1 = RK. | last2 = West | first2 = RB. | title = MOC-31 exhibits superior reactivity compared with Ber-EP4 in invasive lobular and ductal carcinoma of the breast: a tissue microarray study. | journal = Appl Immunohistochem Mol Morphol | volume = 17 | issue = 3 | pages = 202-6 | month = May | year = 2009 | doi =  | PMID = 19391212 }}</ref>
*[[Invasive lobular carcinoma]].<ref name=pmid19391212/>


==See also==
==See also==
*[[Immunohistochemistry]].
*[[Immunohistochemistry]].
*[[Ber-EP4]].


==References==
==References==
48,466

edits

Navigation menu